Drug Profile
Tamsulosin transdermal - Corium International
Alternative Names: Tamsulosin TDS - Corium InternationalLatest Information Update: 11 Dec 2021
Price :
$50
*
At a glance
- Originator Corium International
- Class Amines; Phenyl ethers; Small molecules; Sulfonamides
- Mechanism of Action Alpha-1a adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Benign prostatic hyperplasia
Most Recent Events
- 17 Dec 2018 Corium International has been acquired by Gurnet point capital
- 04 Nov 2017 No recent reports of development identified for phase-I development in Benign-prostatic-hyperplasia(In volunteers) in Australia (Transdermal, Patch)
- 18 Oct 2014 Tamsulosin TDS - Corium International is available for licensing as of 18 Oct 2014. http://www.coriumgroup.com/